Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Changzhou Cancer Hospital of Soochow University
Apatinib is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2). The anti-angiogenesis effect of apatinib has been proved in preclinical tests. Phase II study has showed an improvement of progression free survival in pretreated patients. S-1, an oral fluoropyrimidine has considerable effectiveness with mild side effect in patients failed to standard treatments. The purpose of this study is to evaluate the potential efficacy and safety of low-dose Apatinib combined with S-1 in heavily pretreated patients with advanced lung cancer. And to explore the biomarkers of antiangiogenesis therapy and the possible mechanisms of treatment resistance on the basis of next generation sequencing.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed Non-small cell lung cancer
Patients with extracranial measurable lesions
Patients with NSCLC failed for standard treatments
Eastern Cooperative Oncology Group performance status score: 0\~2 and life expectancy of more than 3 months
Major organs functioning properly
Compliance is good and agreed to cooperate with the survival of follow-up
Informed consent
You may not be if
Contraindications for investigational agents
Patients with clinical symptoms of brain metastases or meningeal metastasis
Tumor invade big vessels or close to big vessels
Uncontrolled hypertension
Abnormal coagulation (INR\>1.5 or Prothrombin Time\>ULN+4, or Activated Partial Thromboplastin Time\>1.5 ULN), bleeding tendency or receiving coagulation therapy
Hemoptysis, more than 2.5ml daily
Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis.
Myocardial ischemia or infarction more than stage II, cardiac insufficiency.
Received big surgery, had bone fracture or ulcer in 4 weeks.
Urine protein≥++, or urine protein in 24 hours≥1.0g
